Epalrestat is a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy by relieving oxidative stress and suppressing the polyol pathway [63, 64]. This evidence concerns the gene AKR1B1 and diabetic neuropathy.